Siga Technologies secures Tecovirimat FDA approval for smallpox treatment
Siga Technologies has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of its orally administered antiviral drug, TPOXX (tecovirimat), for the treatment of smallpox. This approval marks a critical development in public health preparedness and bioterrorism defense. Developed in collaboration with the U.S. Department of Health and Human Services’ Biomedical […]